Last reviewed · How we verify

Control tetanus vaccine, adsorbed

Sinovac Life Sciences Co., Ltd. · Phase 3 active Biologic

This vaccine stimulates the immune system to produce antibodies against tetanus toxin by presenting inactivated tetanus toxoid adsorbed onto an aluminum salt adjuvant.

This vaccine stimulates the immune system to produce antibodies against tetanus toxin by presenting inactivated tetanus toxoid adsorbed onto an aluminum salt adjuvant. Used for Prevention of tetanus in infants, children, and adults.

At a glance

Generic nameControl tetanus vaccine, adsorbed
SponsorSinovac Life Sciences Co., Ltd.
Drug classInactivated bacterial toxoid vaccine
TargetTetanus toxin (tetanospasmin)
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

Tetanus vaccine, adsorbed contains inactivated tetanus toxoid (a detoxified form of the tetanus toxin produced by Clostridium tetani) adsorbed onto aluminum hydroxide or aluminum phosphate. The adjuvant enhances the immunogenicity of the toxoid, promoting a robust humoral immune response that generates protective antibodies against tetanus toxin, conferring immunity against tetanus infection.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: